Outlook Therapeutics Inc - Warrants - Series A (18/02/2022)
OTLKW
Get informed when a big investor buys or sells
+ FollowMarket Cap$121.02M
Close$
Share Statistics
| Market cap | $121.02 Million |
|---|---|
| Enterprise Value | $109.78 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.79 |
| Beta | 0 |
| Outstanding Shares | 136,743,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | -67771217.78% |
| Return on Invested Capital | 1256681106.34% |
Valuation & Multiples
| P/E Ratio | -0.53 |
|---|---|
| PEG | 0.53 |
| Price to Sales | 0.0 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Outlook Therapeutics Inc
8 employees
CEO: Lawrence Kenyon